Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
"Controlling blood sugar levels is very important in the overall treatment and care of diabetes. Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control."
"Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience. Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
"FDA approves three new drug treatments for type 2 diabetes"
Food and Drug Administration
"Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)"
Takeda Pharmaceuticals U.S.A., Inc.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Nordqvist, Joseph. "Three Type 2 Diabetes Pills From Takeda Approved By FDA." Medical News Today. MediLexicon, Intl., 27 Jan. 2013. Web.
9 Dec. 2013. <http://www.medicalnewstoday.com/articles/255487>
Nordqvist, J. (2013, January 27). "Three Type 2 Diabetes Pills From Takeda Approved By FDA." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/255487.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.